5.13
Foghorn Therapeutics Inc stock is traded at $5.13, with a volume of 80,445.
It is up +3.64% in the last 24 hours and up +17.66% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$4.95
Open:
$5.02
24h Volume:
80,445
Relative Volume:
0.66
Market Cap:
$255.30M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.1923
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
+5.56%
1M Performance:
+17.66%
6M Performance:
+6.88%
1Y Performance:
-8.72%
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
FHTX
Foghorn Therapeutics Inc
|
5.13 | 255.30M | 34.16M | -98.43M | -119.33M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
Jan-30-25 | Initiated | B. Riley Securities | Buy |
Sep-03-24 | Initiated | Jefferies | Buy |
Aug-19-24 | Initiated | Evercore ISI | Outperform |
Mar-28-23 | Initiated | BofA Securities | Buy |
Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
Nov-22-21 | Initiated | H.C. Wainwright | Buy |
Nov-17-20 | Initiated | Cowen | Outperform |
Nov-17-20 | Initiated | Goldman | Buy |
Nov-17-20 | Initiated | Morgan Stanley | Overweight |
Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Foghorn Therapeutics Holds Successful Annual Meeting - TipRanks
Bank of America Corp DE Has $149,000 Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, And Clinical Trial Progress Assessment By Delveinsight Oncotherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - MENAFN.com
Soft Tissue Sarcoma Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | OncoTherapy Science, Foghorn Therapeutics, C4 Therapeutics, Lyvgen Biopharma - Barchart.com
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Acquired by Wellington Management Group LLP - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives $12.13 Consensus Target Price from Analysts - Defense World
BNP Paribas Financial Markets Makes New $61,000 Investment in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Trading (FHTX) With Integrated Risk Controls - news.stocktradersdaily.com
Northern Trust Corp Purchases 2,873 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Position Increased by D. E. Shaw & Co. Inc. - Defense World
Lazard Asset Management LLC Acquires New Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire
10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World
(FHTX) Trading Report - news.stocktradersdaily.com
Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World
Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World
JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN
FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus
FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus
Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire
Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView
FHTX Exceeds Revenue Expectations and Advances Pipeline Programs | FHTX Stock News - GuruFocus
Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World
Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan
Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
(FHTX) Trading Advice - news.stocktradersdaily.com
Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World
JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India
Foghorn Therapeutics expands board with biotech veterans - Investing.com
Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus
Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Foghorn Therapeutics Inc Stock (FHTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Costa Carlos | Chief People Officer |
Sep 23 '24 |
Option Exercise |
3.72 |
857 |
3,188 |
857 |
Costa Carlos | Chief People Officer |
Sep 20 '24 |
Sale |
10.04 |
35,756 |
358,990 |
0 |
Costa Carlos | Chief People Officer |
Sep 23 '24 |
Sale |
10.17 |
857 |
8,716 |
0 |
Costa Carlos | Chief People Officer |
Sep 18 '24 |
Option Exercise |
3.72 |
11,574 |
43,055 |
11,574 |
Costa Carlos | Chief People Officer |
Sep 18 '24 |
Sale |
10.05 |
11,574 |
116,319 |
0 |
Costa Carlos | Chief People Officer |
Sep 17 '24 |
Option Exercise |
3.72 |
10,272 |
38,212 |
10,272 |
Costa Carlos | Chief People Officer |
Sep 16 '24 |
Option Exercise |
3.72 |
400 |
1,488 |
400 |
Costa Carlos | Chief People Officer |
Sep 17 '24 |
Sale |
10.04 |
10,272 |
103,131 |
0 |
Costa Carlos | Chief People Officer |
Sep 16 '24 |
Sale |
10.00 |
400 |
4,000 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):